Connect have questions about fibryga or Octapharma?

Find your Rep

To request product information or an on‑label in‑service program by an Octapharma representative, please call the customer service hotline: 866‑766‑4860.

Enter your ZIP code to find the Octapharma representative near you:

Error: Please enter a valid first name.

Error: Please enter a valid last name.

Error: Please enter a valid email address.

Error: Please enter a valid NPI number.

Add Mailing Address (Optional)

Terms & Conditions: By submitting this form, I understand and agree to the Octapharma Privacy Policy and Terms of Use. I agree to be contacted by an Octapharma representative and to receive communications from Octapharma.

Error: Please accept the T&Cs.

Thank you for signing up for updates

Please check your email for updates about fibryga and learn more about early fibrinogen replacement in bleeding patients with acquired fibrinogen deficiency (AFD).

Looking for other helpful resources?

Connect with Octapharma Medical AffairsGet assistance

Indications & Important Safety Information for Fibryga, Fibrinogen (Human)

Indications and Usage

Fibryga is a human fibrinogen concentrate indicated for fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency and in treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Fibryga is not indicated for dysfibrinogenemia.

Contraindications

Fibryga is contraindicated in individuals who have manifested severe immediate hypersensitivity reactions, including anaphylaxis, to fibryga or its components (Sodium Citrate Dihydrate; Glycine; L-Arginine Hydrochloride).

Warnings and Precautions

Monitor patients for early signs of hypersensitivity or allergic reactions. If necessary, discontinue administration and institute appropriate treatment.

Thrombotic events have been reported in patients receiving fibryga. Treatment with human fibrinogen concentrate has been associated with thrombosis at target plasma fibrinogen levels that were below 150 mg/dL. The thrombotic risks may be greater when the target fibrinogen plasma level is 150 mg/dL. Weigh the benefits of administration versus the risks of thrombosis.

Fibryga is made from pooled human plasma. Products made from human plasma may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Adverse Reactions

The most serious adverse reactions observed with fibryga are thromboembolic episodes and anaphylactic-type reactions.

The most common adverse reactions observed in clinical studies with fibryga in acquired fibrinogen deficiency (>5% of patients) were abnormal hepatic function, acute kidney injury, anemia, atrial fibrillation, delirium and renal failure.

The most common adverse reactions observed in clinical studies with fibryga in congenital fibrinogen deficiency (>5% of patients) were nausea, vomiting, pyrexia (fever) and thrombocytosis.

Please see fibryga full Prescribing Information.

To report suspected adverse reactions, contact Octapharma USA, Inc. at 1-866-766-4860 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.